BMEA BIOMEA FUSION INC

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference

SAN CARLOS, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Mick Hitchcock, Ph.D., Interim Chief Executive Officer and Board Member, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 from 5:15 PM to 5:55 PM Pacific Time. Additionally, Biomea’s management team will host one-on-one meetings throughout the conference, which will take place from January 12-15.

A live audio webcast of the presentation can be accessed or by visiting the Investors & Media section of Biomea’s website at . A replay of the webcast will be available following the live presentation.

About Biomea Fusion

Biomea Fusion is a clinical-stage biopharmaceutical company advancing oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.

Visit us at biomeafusion.com and follow us on , and .

Contact:

Meichiel Jennifer Weiss

Sr. Director of Investor Relations and Corporate Development



EN
17/12/2025

Underlying

BMEABIOMEA FUSION INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOMEA FUSION INC

 PRESS RELEASE
Free
BMEA BIOMEA FUSION I...

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Con...

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference SAN CARLOS, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Mick Hitchcock, Ph.D., Interim Chief Executive Officer and Board Member, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 from 5:15 PM to 5:55 PM Pacific Time. Additionally, Biomea’s management team will host one-on-one meetings throughout the conference, which will take place from January 12-15. A...

6h / 35m 1 EN
 PRESS RELEASE
Free
BMEA BIOMEA FUSION I...

Biomea Fusion Announces KOL Presentation and Interview on Menin and Ic...

Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025 Key Opinion Leader, Dr. Ralph DeFronzo presents the “Future of Menin Inhibitors” and discusses icovamenib and its clinical results shared during WCIRDC 2025 in online interview SAN CARLOS, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical stage diabetes and obesity company, today announced the release of a KOL interview during the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC 2025) featuring Dr. Ralph DeFronzo, Profess...

December 9, 2025 1 EN
 PRESS RELEASE
Free
BMEA BIOMEA FUSION I...

Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Co...

Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) Durable Glycemic and C-Peptide Improvements with Icovamenib in Insulin-Deficient Type 2 Diabetes SAN CARLOS, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it presented COVALENT-111 study results at the 23rd WCIRDC which took place December 3-6, 2025 in Los Angeles, California. The data showed durable g...

December 5, 2025 1 EN
 PRESS RELEASE
Free
BMEA BIOMEA FUSION I...

Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd Wo...

Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has been selected for an oral presentation of its long-term icovamenib follow up data at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) taking place in Los Angeles, California on December 3-6, 20...

December 1, 2025 1 EN
 PRESS RELEASE
Free
BMEA BIOMEA FUSION I...

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule...

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on November 26, 2025, the compensation committee of Biomea’s board of directors granted one new employee non-qualified stock options to purchase 7,500 shares of the Company’s common stock. The shares underlying each employee’s stock options will vest 1/16 on a quarterly basis over four years, subject to such employe...

December 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch